ArihantCapital
Generating Wealth

Q1FY26 Result update
13th Aug 2025

# India Glycols Ltd

**De-merger is expected to unlock value.**

**CMP: INR 858**

**Rating: BUY**

**Target Price: INR 1,188**

| Stock Info | |
|---|---|
| BSE | 500201 |
| NSE | INDIAGLYCO |
| Bloomberg | IGLY:IN |
| Reuters | IGLY.NS |
| Sector | Chemicals |
| Face Value (INR cr) | 10 |
| Equity Capital (INR cr) | 31 |
| Mkt Cap (INR cr) | 5,313 |
| 52w H/L (INR) | 1,070 / 502 |
| Avg Yearly Volume (in 000') | 195.6 |

| Shareholding Pattern % *(As on Jun 2025)* | |
|---|---|
| Promoters | 61.02 |
| DII | 1.39 |
| FII | 3.44 |
| Public & Others | 34.15 |

| Stock Performance (%) | 3m | 6m | 12m |
|---|---|---|---|
| IGL | 4.5 | 42.2 | 33.3 |
| NIFTY | -0.4 | 6.3 | 0.6 |

**IGL vs Nifty**





**Abhishek Jain**
abhishek.jain@arihantcapital.com
022-67114871

**Balasubramanian A**
bala@arihantcapital.com
022-67114870


**India Glycols Ltd** reported numbers, Q1FY26 revenue stood at INR 1,040cr (+7.4% YoY/+20.5% QoQ); below our estimates of INR 1,097cr. Gross Profit stood at INR 363cr (+6.3% YoY/+10.2% QoQ); below our estimates of INR 388cr. Gross margins contracted by 36 bps YoY (-326 bps QoQ) to 34.9% vs 35.3% in Q1FY25. The margin contraction mainly because of raw material cost increase in terms of sales. The raw material cost in terms of sales stood at 65.1% vs 64.7% in Q1FY25. EBITDA stood at INR 150cr (+19.2% YoY/+2.5% QoQ); above our estimates of INR 146cr. EBITDA margin improved by 142 bps YoY (-252 bps QoQ) to 14.4% vs 13.0% in Q1FY25. PAT stood at INR 73cr (+21.3% YoY/+14.4% QoQ); above our estimates of INR 70cr. PAT margin improved by 81 bps YoY (-38 bps QoQ) to 7.0% vs 6.2% in Q1FY25.

## Key Highlights

**Potable Spirits growth led by country liquor and IMFL:** Potable Spirits revenue stood at INR 342cr (+22.4% YoY/+20.6% QoQ); EBIT Stood at INR 72cr (+47.4% YoY/-7.8% QoQ). EBIT margin improved by 358 bps YoY (-649 bps QoQ) to 21.1% vs 17.5% in Q1FY25. The company has an iconic brand Bunty Bubli brand which, commands 16% market share, provides stable cash flows and pricing power. The strategic partnership with Amrut unlocks premiumization opportunities in the fast-growing IMFL segment, while expansion into new geographies like Kerala and institutional channels (paramilitary, CSD) diversifies revenue streams.

**Bio-fuels remain a structural growth engine:** Bio-fuel revenue stood at INR 348cr (+45.4% YoY/+27.1% QoQ); EBIT Stood at INR 23cr (+21.4% YoY/+42.6% QoQ). EBIT margin contracted by 129 bps YoY (+71 bps QoQ) to 6.5% vs 7.8% in Q1FY25. The ethanol blending targets increasing to 20% and potentially 25-30% by 2030. The company has a first-mover advantage in grain-based ethanol, ensures steady demand visibility. The government's administered pricing mechanism provides margin stability despite feedstock volatility, making this a predictable, policy-backed growth engine.

**Focus remain on value-added products in chemicals:** Bio based specialties and performance chemicals revenue stood at INR 300cr (-23.7% YoY/+18% QoQ); EBIT Stood at INR 33cr (-16% YoY/+12.2% QoQ). EBIT margin improved by 100 bps YoY (-56 bps QoQ) to 10.9% vs 9.9% in Q1FY25. The company pivots from commoditized products to high-value specialty chemicals. Chemicals facing near-term headwinds from crude-based MEG competition; however, the company focuses on green chemistry solutions, oilfield chemicals, and crop protection formulations, positions it well for sustainable growth.

**Outlook & Valuation: India Glycols is restructuring and de-merging into 3 businesses separately and it would lead to independent growth for each business and unlock value going forward. Bunty Bubli is the highest selling brand with 16% market share in the country liquor and Amrut Partnership brands ranged between INR 850-1,100 labels gaining traction and secured 10% market share within 1 year of launch. The potable spirits segment will continue to benefit from strong brand loyalty in country liquor and premiumization through its Amrut partnership, driving both volumes and margins. The biofuels business remains a key growth driver, supported by India's rising ethanol blending targets and stable government pricing policies. In chemicals, the focus on high-value specialty products and the Clariant JV's strong performance should sustain margin expansion despite competitive pressures. Ennature Biopharma faces near-term challenges, its shift toward branded nutraceuticals and regulated market approvals could improve profitability over time. The company's disciplined debt reduction, restructuring plans, and diversified revenue streams provide resilience, making it a balanced play on India's consumption, energy transition, and specialty chemicals trends. At the CMP of INR 858 per share, we maintain our "BUY" rating at a TP of INR 1,188 per share; based on SOTP; an upside of 38.4%.**

## Q1FY26 Results

**Income statement summary**

| Particular (INR cr) | Q1FY25 | Q4FY25 | Q1FY26 | YoY (%) | QoQ (%) |
|---|---|---|---|---|---|
| **Revenue** | **969** | **863** | **1,040** | **7.4%** | **20.5%** |
| Net Raw Materials | 627 | 534 | 677 | 8.0% | 26.9% |
| **Gross Profit** | **341** | **329** | **363** | **6.3%** | **10.2%** |
| **Gross Margin (%)** | **35.3%** | **38.2%** | **34.9%** | **-36 bps** | **-356 bps** |
| Power & Fuel | 89 | 75 | 92 | 2.4% | 21.3% |
| Employee Cost | 31 | 31 | 31 | 1.3% | 1.6% |
| Other Expenses | 96 | 77 | 91 | -5.3% | 17.3% |
| **EBITDA** | **126** | **146** | **150** | **19.2%** | **2.5%** |
| **EBITDA Margin (%)** | **13.0%** | **16.9%** | **14.4%** | **+142 bps** | **-252 bps** |
| Depreciation | 28 | 33 | 34 | | |
| Interest expense | 36 | 45 | 45 | | |
| Other income | 3 | 2 | 1 | | |
| Share of profits associate & JV | 11 | 11 | 19 | | |
| **Profit before tax** | **76** | **82** | **91** | **19.7%** | **10.7%** |
| Taxes | 15 | 18 | 17 | | |
| **PAT** | **60** | **64** | **73** | **21.3%** | **14.4%** |
| **PAT Margin (%)** | **6.2%** | **7.4%** | **7.0%** | **+81 bps** | **-38 bps** |
| Other Comprehensive income | (0) | (1) | (0) | | |
| **Total Comprehensive income** | **60** | **63** | **73** | **20.7%** | **15.1%** |
| **EPS (INR)** | **19.5** | **20.7** | **23.7** | | |

*Source: Company Reports, Arihant Capital Research*

**Exhibit 1: Gross margins contracted by 36 bps YoY (-356 bps QoQ) to 34.9% in Q1FY26 due to higher raw material costs.**




*Source: Company Reports, Arihant Capital Research*

**Exhibit 2: EBITDA margin improved by 142 bps YoY (-252 bps QoQ) to 14.4% in Q1FY26; led by lower power & fuel cost, employee and other expenses in-terms of sales.**




*Source: Company Reports, Arihant Capital Research*

**Exhibit 3: Power & fuel costs remain below 9%. The company signed agreement with Renew Green to procure captive wind and solar hybrid power. It will reduce power cost going forward.**




*Source: Company Reports, Arihant Capital Research*

**Exhibit 4: EBIT margin improved by 100 bps YoY (-56 bps QoQ) to 10.9% in Q1FY26, supported by value added products.**




*Source: Company Reports, Arihant Capital Research*
*BSPC - Bio-based Specialities and Performance Chemicals*

**Exhibit 5: Excise duty moderating gradually.**




*Source: Company Reports, Arihant Capital Research*

**Exhibit 6: EBIT margin improved by 358 bps YoY (-649 bps QoQ) to 21.1% in Q1FY26. The premiumization efforts and Amrut partnership would contribute more expansion going forward.**




*Source: Company Reports, Arihant Capital Research*

**Exhibit 7: EBIT margin contracted by 898 bps YoY (-595 bps QoQ) to 2.4% in Q1FY26 due to price erosion of thiocolchicoside and nicotine.**




*Source: Company Reports, Arihant Capital Research*

**Exhibit 8: Bio-fuel revenue share is around 33.4% in Q1FY26.**




*Source: Company Reports, Arihant Capital Research*

## Q1FY26 Concall Highlights

**Potable Spirits**

- Bunty Bubli remains the highest-selling liquor brand in India for three consecutive years.
- Bunty Bubli commands 16% market share in the country liquor segment and dominates in Uttar Pradesh and Uttarakhand.
- The company introduced premium whiskey brands like McIntosh White Label (priced at INR 850) and McIntosh Black Label (INR 1,100) through a partnership with Amrut. These brands secured 10% market share within a year of launch in Delhi.
- The company is prioritizing premiumization in the potable spirits segment, leveraging the Amrut partnership to capture higher-value markets.
- The company has a 24%-25% market share in Uttar Pradesh.
- The company has entered Kerala, a high-potential market, with brands like Zumba, Lemoni, and Amazing Vodka. It is also eyeing opportunities in the CSD (Canteen Stores Department) segment, which serves defense personnel, further diversifying its distribution channels
- The company has expanded into the paramilitary segment, supplying five brands and emerging as one of the top four suppliers in this niche market.
- The company manufactures and markets brands under a long-standing partnership with Bacardi, producing high-quality spirits such as Breezer and Bacardi Lemon at its Kashipur facility.

**Bio-fuels**

- Biofuels segments witnessed strong growth, supported by government policies promoting ethanol blending.
- The company expects continued growth as India targets 20% ethanol blending by 2025, potentially increasing to 25%-30% by 2030.
- In biofuels, feedstock availability (damaged food grains, corn) is managed under government mechanisms, mitigating significant risks.
- Biofuels margins faced slight pressure due to feedstock costs, but the business remains stable with government-administered pricing ensuring steady profitability.

**Chemicals**

- The chemicals segment faces competition from crude-based MEG, but the company is diversifying into greener alternatives.
- The company is strategically pivoting toward value-added performance chemicals to enhance margins and reduce dependency on commoditized products.
- Its includes innovations in oilfield chemicals, crop protection solutions, and bio-based surfactants, where the company collaborates with global partners to develop customized formulations.

## Q1FY26 Concall Highlights

**JV**
- The joint venture with Clariant performed exceptionally well, driven by better product mix and cost efficiencies.

**Ennature Biopharma**
- Ennature Biopharma faced challenges with slowing demand in developed markets and margin pressures due to new entrants.

- In Ennature Biopharma, nicotine and thiocolchicoside are under pressure, but differentiated products and new market entries are expected to stabilize performance.

- The company is focusing on differentiation through regulatory approvals, impurity profiling, and expanding into nutraceuticals. The company plans to launch branded nutraceuticals in the US and Europe to improve margins in the upcoming quarters.

**Capex**
- The capex is expected to be INR 40-50cr in FY26E, primarily for maintenance.

**Debt repayment**
- The company plans to repay INR 300cr of debt using internal accruals, reducing leverage.

**Other highlights**
- The demerger of businesses into separate entities (India Glycols Ltd, IGL Spirits Ltd, Ennature Biopharma Ltd) aims to unlock shareholder value by catering to different investor appetites.

## Financial Statements

**Income statement summary**

| Y/e 31 Mar (INR cr) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,735 | 2,317 | 2,868 | 2,651 | 3,294 | 3,768 | 4,078 | 4,657 |
| Net Raw Materials | 1,846 | 1,499 | 1,921 | 1,582 | 2,149 | 2,408 | 2,607 | 2,975 |
| Power & Fuel | 250 | 214 | 332 | 417 | 328 | 362 | 384 | 436 |
| Employee Cost | 93 | 83 | 89 | 89 | 103 | 123 | 129 | 145 |
| Other Expenses | 267 | 253 | 444 | 267 | 311 | 365 | 380 | 429 |
| **EBITDA** | **279** | **268** | **81** | **296** | **402** | **511** | **578** | **672** |
| **EBITDA Margin (%)** | **10.2%** | **11.6%** | **2.8%** | **11.1%** | **12.2%** | **13.6%** | **14.2%** | **14.4%** |
| Depreciation | (78) | (80) | (80) | (94) | (101) | (115) | (140) | (145) |
| Interest expense | (97) | (83) | (70) | (100) | (121) | (164) | (175) | (154) |
| Other income | 9 | 15 | 22 | 24 | 26 | 15 | 14 | 16 |
| Exceptional Items | - | - | 221 | 28 | - | - | - | - |
| Share of profits associate & JV | (0) | 1 | 21 | 11 | 17 | 46 | 69 | 79 |
| **Profit before tax** | **113** | **120** | **195** | **165** | **223** | **292** | **347** | **468** |
| Taxes | (38) | (11) | (39) | (24) | (50) | (61) | (82) | (118) |
| **PAT** | **75** | **109** | **156** | **141** | **173** | **231** | **265** | **350** |
| **PAT from discontinued operations** | 40 | 22 | 10 | - | - | - | - | - |
| **PAT** | **115** | **132** | **166** | **141** | **173** | **231** | **265** | **350** |
| **PAT Margin (%)** | **4.2%** | **5.7%** | **5.8%** | **5.3%** | **5.3%** | **6.1%** | **6.5%** | **7.5%** |
| Other Comprehensive income | (1) | 3 | (0) | 0 | (0) | (1) | - | - |
| **Net profit** | **113** | **135** | **166** | **141** | **173** | **229** | **265** | **350** |
| EPS (INR) | 18.3 | 21.7 | 26.7 | 22.8 | 27.9 | 37.1 | 42.8 | 56.5 |

*Source: Company Reports, Arihant Capital Research*

**Balance sheet summary**

| Y/e 31 Mar (INR cr) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 31 | 31 | 31 | 31 | 31 | 31 | 31 | 31 |
| Reserves | 1,003 | 1,138 | 1,761 | 1,870 | 2,020 | 2,225 | 2,453 | 2,754 |
| **Net worth** | 1,034 | 1,169 | 1,792 | 1,901 | 2,051 | 2,256 | 2,484 | 2,785 |
| Minority Interest | - | - | (19) | - | - | - | - | - |
| Provisions | 14 | 9 | 8 | 7 | 8 | 8 | 2 | 3 |
| Debt | 1,335 | 1,444 | 1,367 | 1,479 | 1,763 | 2,309 | 2,004 | 1,799 |
| Other non-current liabilities | 613 | 619 | 527 | 475 | 401 | 445 | 489 | 559 |
| **Total Liabilities** | **2,996** | **3,241** | **3,675** | **3,863** | **4,223** | **5,018** | **4,979** | **5,145** |
| Fixed assets | 2,201 | 2,171 | 2,303 | 2,690 | 3,171 | 3,736 | 3,764 | 3,783 |
| Capital Work In Progress | 172 | 126 | 243 | 125 | 84 | 98 | 93 | 97 |
| Other Intangible assets | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 |
| Investments | 83 | 83 | 456 | 370 | 384 | 427 | 408 | 466 |
| Other non current assets | 33 | 27 | 19 | 25 | 31 | 96 | 37 | 42 |
| **Net working capital** | **354** | **684** | **362** | **368** | **286** | **527** | **468** | **629** |
| Inventories | 682 | 610 | 693 | 754 | 1,106 | 1,171 | 1,157 | 1,239 |
| Sundry debtors | 569 | 362 | 399 | 430 | 384 | 365 | 469 | 510 |
| Loans & Advances | 26 | 26 | 26 | 0 | 1 | 1 | 41 | 47 |
| Other current assets | 167 | 564 | 201 | 179 | 189 | 149 | 201 | 204 |
| Sundry creditors | (722) | (581) | (642) | (752) | (1,099) | (979) | (1,074) | (1,092) |
| Other current liabilities & Prov | (369) | (297) | (314) | (244) | (295) | (179) | (326) | (279) |
| Cash | 92 | 98 | 102 | 113 | 138 | 77 | 150 | 63 |
| Other Financial Assets | 60 | 51 | 188 | 170 | 127 | 54 | 57 | 65 |
| **Total Assets** | **2,996** | **3,241** | **3,675** | **3,863** | **4,223** | **5,018** | **4,979** | **5,145** |

*Source: Company Reports, Arihant Capital Research*

## Financial Statements

**Cashflow summary**

| Y/e 31 Mar (INR cr) | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|---|---|---|---|
| Profit before tax | 113 | 120 | 195 | 165 | 223 | 292 | 347 | 468 |
| Depreciation | 78 | 80 | 80 | 94 | 101 | 115 | 140 | 145 |
| Tax paid | (38) | (11) | (39) | (24) | (50) | (61) | (82) | (118) |
| Working capital Δ | (41) | (330) | 322 | (6) | 81 | (241) | 59 | (161) |
| **Operating cashflow** | **111** | **(141)** | **558** | **229** | **355** | **105** | **465** | **335** |
| Capital expenditure | (148) | (4) | (330) | (362) | (541) | (695) | (163) | (167) |
| **Free cash flow** | **(37)** | **(145)** | **228** | **(133)** | **(186)** | **(590)** | **301** | **168** |
| Equity raised | 41 | 26 | 486 | (8) | (0) | (1) | - | - |
| Investments | (3) | 0 | (374) | 86 | (14) | (43) | 19 | (58) |
| Others | (20) | 14 | (128) | 12 | 37 | 8 | 56 | (13) |
| Debt financing/disposal | 81 | 110 | (97) | 131 | 284 | 546 | (305) | (205) |
| Dividends paid | (44) | (0) | (18) | (23) | (23) | (25) | (37) | (49) |
| Other items | (40) | 1 | (93) | (53) | (74) | 45 | 38 | 70 |
| **Net Δ in cash** | **(24)** | **6** | **4** | **12** | **25** | **(60)** | **73** | **(88)** |
| **Opening Cash Flow** | **116** | **92** | **98** | **102** | **113** | **138** | **77** | **150** |
| **Closing Cash Flow** | **92** | **98** | **102** | **113** | **138** | **77** | **150** | **63** |

*Source: Company Reports, Arihant Capital Research*

**Ratio analysis**

| Y/e 31 Mar | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26E | FY27E |
|---|---|---|---|---|---|---|---|---|
| **Growth matrix (%)** | | | | | | | | |
| Revenue growth | -18.5% | -15.3% | 23.8% | -7.6% | 24.3% | 14.4% | 8.2% | 14.2% |
| Op profit growth | -33.1% | -3.9% | -69.6% | 263.3% | 36.1% | 26.9% | 13.2% | 16.2% |
| Net profit growth | -13.5% | 14.8% | 26.1% | -15.0% | 22.7% | 33.4% | 14.9% | 32.1% |
| **Profitability ratios (%)** | | | | | | | | |
| OPM | 10.2% | 11.6% | 2.8% | 11.1% | 12.2% | 13.6% | 14.2% | 14.4% |
| Net profit margin | 3.2% | 4.0% | 4.2% | 5.7% | 5.8% | 5.3% | 5.3% | 6.1% |
| RoCE | 6.1% | 7.4% | 0.6% | 5.9% | 7.0% | 7.7% | 7.6% | 8.9% |
| RoNW | 7.5% | 9.9% | 10.5% | 7.6% | 8.8% | 10.7% | 11.2% | 13.3% |
| RoA | 2.5% | 3.4% | 4.2% | 3.7% | 4.1% | 4.6% | 5.3% | 6.8% |
| **Per share ratios (INR)** | | | | | | | | |
| EPS | 18.3 | 21.7 | 26.7 | 22.8 | 27.9 | 37.1 | 42.8 | 56.5 |
| Dividend per share | 7.2 | 0.1 | 3.0 | 3.7 | 3.7 | 4.0 | 6.0 | 7.9 |
| Cash EPS | 24.6 | 30.6 | 38.1 | 38.0 | 44.2 | 55.9 | 65.4 | 80.0 |
| Book value per share | 167.0 | 188.7 | 289.4 | 307.1 | 331.2 | 364.3 | 401.1 | 449.8 |
| **Valuation ratios (x)** | | | | | | | | |
| P/E | 46.9 | 39.5 | 32.1 | 37.6 | 30.7 | 23.2 | 20.0 | 15.2 |
| P/CEPS | 34.9 | 28.1 | 22.5 | 22.6 | 19.4 | 15.4 | 13.1 | 10.7 |
| P/B | 5.1 | 4.5 | 3.0 | 2.8 | 2.6 | 2.4 | 2.1 | 1.9 |
| EV/EBITDA | 23.2 | 24.5 | 75.3 | 21.3 | 16.3 | 13.9 | 11.7 | 9.8 |
| **Payout (%)** | | | | | | | | |
| Dividend payout | 59.2% | 0.4% | 11.8% | 16.3% | 13.3% | 10.7% | 14.0% | 14.0% |
| Tax payout | 33.6% | 9.4% | 20.2% | 14.5% | 22.5% | 21.0% | 23.6% | 25.2% |
| **Liquidity ratios** | | | | | | | | |
| Debtor days | 59 | 73 | 48 | 57 | 45 | 36 | 37 | 38 |
| Inventory days | 131 | 157 | 124 | 167 | 158 | 173 | 163 | 147 |
| Creditor days | 109 | 116 | 80 | 108 | 117 | 116 | 107 | 99 |
| WC Days | 82 | 115 | 92 | 116 | 86 | 92 | 93 | 86 |
| **Leverage ratios (x)** | | | | | | | | |
| Interest coverage | 2.1 | 2.3 | 0.0 | 2.0 | 2.5 | 2.4 | 2.5 | 3.4 |
| Net debt / equity | 1.2 | 1.2 | 0.7 | 0.7 | 0.8 | 1.0 | 0.7 | 0.6 |
| Net debt / op. profit | 4.5 | 5.0 | 15.6 | 4.6 | 4.0 | 4.4 | 3.2 | 2.6 |

*Source: Company Reports, Arihant Capital Research*

**Outlook & Valuation: India Glycols is restructuring and de-merging into 3 businesses separately and it would lead to independent growth for each business and unlock value going forward. Bunty Bubli is the highest selling brand with 16% market share in the country liquor and Amrut Partnership brands ranged between INR 850-1,100 labels gaining traction and secured 10% market share within 1 year of launch. The potable spirits segment will continue to benefit from strong brand loyalty in country liquor and premiumization through its Amrut partnership, driving both volumes and margins. The biofuels business remains a key growth driver, supported by India's rising ethanol blending targets and stable government pricing policies. In chemicals, the focus on high-value specialty products and the Clariant JV's strong performance should sustain margin expansion despite competitive pressures. Ennature Biopharma faces near-term challenges, its shift toward branded nutraceuticals and regulated market approvals could improve profitability over time. The company's disciplined debt reduction, restructuring plans, and diversified revenue streams provide resilience, making it a balanced play on India's consumption, energy transition, and specialty chemicals trends. At the CMP of INR 858 per share, we maintain our "BUY" rating at a TP of INR 1,188 per share; based on SOTP; an upside of 38.4%.**

| IGL FY27E based implied valuation | IGL Spirits | India Glycols | Ennature Biopharma | |
|---|---|---|---|---|
| FY27E EBITDA (INR cr) | 557 | 143 | 17 | |
| EV/EBITDA (x) | **15.0x** | **5.0x** | **1.0x** | |
| EV (INR cr) | 8,357 | 717 | 17 | 9,091 |
| Net Debt/(cash) (INR cr) - FY27E end | | | | 1,736 |
| Market Cap (INR cr) | | | | 7,355 |
| Share outstanding (cr) | | | | 6.2 |
| **Value per share (INR) - FY27E** | | | | **1,188** |
| **CMP (INR)** | | | | **858** |
| **Upside/Downside (%)** | | | | **38.4%** |

*Source: Company reports, Arihant Capital Research*

## Story in Charts

**Exhibit 9: Potable spirits and Biofuels will drive the growth going forward.**




**Exhibit 10: The capex completed for grain based distilleries and it would reduce raw material costs and improve gross margin levels.**




**Exhibit 11: The captive wind and solar hybrid power will reduce costs going forward.**




**Exhibit 12: Growth in EBITDA & PAT levels.**




**Exhibit 13: Working capital days to be improve**




**Exhibit 14: Cash flows to be improve**




*Source: Company Reports, Arihant Capital Research*

## Story in Charts

**Exhibit 15: Return ratios to be improve.**




**Exhibit 16: Working capital is expected to be below 15% in terms of sales going forward.**




**Exhibit 17: Cash conversion cycle is expected to maintain going forward.**




**Exhibit 18: Net debt reduction is expected going forward.**




**Exhibit 19: Ethanol blending and recovery in BSPC and Potable Sprits will drive growth.**




**Exhibit 20: Segment wise mix**




*Source: Company Reports, Arihant Capital Research*

**Arihant Research Desk**

Email: instresearch@arihantcapital.com

Tel. : 022-42254800

| Head Office | Registered Office |
|---|---|
| #1011, Solitaire Corporate Park | |
| Building No. 10, 1st Floor | 6 Lad Colony, |
| Andheri Ghatkopar Link Road | Y.N. Road, |
| Chakala, Andheri (E) | Indore - 452003, (M.P.) |
| Mumbai – 400093 | Tel: (91-731) 4217100/101 |
| Tel: (91-22) 42254800 | CIN: L66120MP1992PLC007182 |

| Stock Rating Scale | Absolute Return |
|---|---|
| BUY | >20% |
| ACCUMULATE | 12% to 20% |
| HOLD | 5% to 12% |
| NEUTRAL | -5% to 5% |
| REDUCE | -5% to -12% |
| SELL | <-12% |

| Research Analyst Registration No. | Contact | Website | Email Id |
|---|---|---|---|
| INH000002764 | SMS: 'Arihant' to 56677 | www.arihantcapital.com | instresearch@arihantcapital.com |

**Arihant Capital Markets Ltd.**
1011, Solitaire Corporate park, Building No. 10, 1st Floor,
Andheri Ghatkopar Link Road, Chakala, Andheri (E)
Tel. 022-42254800

**Disclaimer:** This disclosure statement is provided in compliance with the SEBI Research Analyst Regulations, 2014. Arihant Capital Markets Limited (ACML) is a registered stockbroker, merchant banker, and research analyst under SEBI, and is also a Point of Presence with the Pension Fund Regulatory and Development Authority (PFRDA). ACML is registered with SEBI with Research Analyst Registration Number INH000002764, Stock Broker Registration Number INZ000180939, and is a Trading Member with NSE, BSE, MCX, NCDEX, and a Depository Participant with CDSL and NSDL.

ACML and its associates may have business relationships, including investment banking, with companies covered by its Investment Research Department. The analysts of ACML, and their associates, are prohibited from holding a financial interest in securities or derivatives of companies they cover, though they may hold stock in the companies they analyze. The recommendations provided by ACML's research team are based on technical and derivative analysis and may differ from fundamental research reports.

ACML confirms that neither it nor its associates have a financial interest or material conflict concerning the companies covered in the research report at the time of publication. Furthermore, ACML, its analysts, and their relatives have no ownership greater than 1% in the subject companies as of the month prior to publication. ACML guarantees that the compensation for its research analysts is not influenced by specific securities or transactions.

ACML affirms that neither the analyst nor the company has served as an officer, director, employee, or engaged in market-making activities for any of the subject companies. Additionally, the research report does not reflect any conflict of interest and is not influenced by specific recommendations made. Neither ACML nor its analysts have received compensation for investment banking or brokerage services from the subject companies in the last 12 months.

The views expressed in this report are those of the analysts and are independent of the proprietary trading desk of ACML, which operates separately to maintain an unbiased stance. Analysts comply with SEBI Regulations when offering recommendations or opinions through public media. The report is intended for informational purposes only and is not an offer or solicitation for the purchase or sale of securities.

This report, which is confidential, may not be reproduced or shared without written consent from ACML. It is based on publicly available data believed to be reliable but has not been independently verified, and no guarantees are made about its accuracy. All opinions and information contained in the report are subject to change without notice. ACML disclaims liability for any losses resulting from reliance on this report. The report does not constitute an offer to buy or sell securities, and ACML is not responsible for the risks involved in investments. ACML and its affiliates may have positions in the securities discussed or hold other financial interests in them.

The distribution of this report in certain jurisdictions may be restricted by law, and the report is not intended for distribution where it would violate local laws. Investors are advised to consider their financial position, risk tolerance, and investment objectives before engaging in transactions, particularly in high-risk financial products such as derivatives.

ACML reserves the right to modify this disclosure statement without prior notice. The report has been prepared using publicly available information and internally developed data, though ACML does not guarantee its completeness or accuracy. Historical price data for securities can be accessed via official exchanges like NSE or BSE. ACML and its affiliates may conduct proprietary transactions or investment banking services for the companies mentioned in this report. In compliance with SEBI regulations, ACML maintains comprehensive records of research reports, recommendations, and the rationale for those recommendations, which are preserved for at least five years. An annual compliance audit is conducted by a member of the ICAI or ICSI to ensure adherence to applicable regulations. This report is issued in accordance with applicable SEBI regulations and does not guarantee future performance or returns.

**Arihant Capital Markets Ltd.**
1011, Solitaire Corporate park, Building No. 10, 1st Floor,
Andheri Ghatkopar Link Road, Chakala, Andheri (E)
Tel. 022-42254800